GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
13.15
-0.94 (-6.67%)
Mar 27, 2026, 4:00 PM EDT - Market closed
Company Description
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.
GH Research PLC
| Country | Ireland |
| Founded | 2018 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Velichka Valcheva |
Contact Details
Address: Joshua Dawson House, Dawson Street Dublin, D02 RY95 Ireland | |
| Phone | 353 1 437 8334 |
| Website | ghres.com |
Stock Details
| Ticker Symbol | GHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1855129 |
| CUSIP Number | G3855L106 |
| ISIN Number | IE000GID8VI0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer |
| Florian Schonharting M.Sc. (Econ) | Co-Founder and Non-Executive Chairman of the Board |
| Magnus Halle | Co-Founder and MD of Ireland |
| Julie Ryan F.C.A. | Vice President of Finance |
| Aaron Cameron M.B.A. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2026 | 6-K | Report of foreign issuer |
| Mar 16, 2026 | 6-K | Report of foreign issuer |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 22, 2026 | 6-K | Report of foreign issuer |
| Jan 15, 2026 | 6-K | Report of foreign issuer |
| Jan 13, 2026 | 6-K | Report of foreign issuer |
| Jan 8, 2026 | 6-K | Report of foreign issuer |